123 related articles for article (PubMed ID: 25618630)
21. Clinical perspectives on dose escalation for non-small-cell lung cancer.
Chang AJ; Bradley JD
Clin Lung Cancer; 2010 Sep; 11(5):299-302. PubMed ID: 20837454
[TBL] [Abstract][Full Text] [Related]
22. A New Immunotherapy Drug Creates a Watershed for the Surgical Pathologist's Role in Patient Care.
Cagle PT; Bernicker EH
Arch Pathol Lab Med; 2015 Nov; 139(11):1329. PubMed ID: 26516934
[No Abstract] [Full Text] [Related]
23. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
24. PD-1 inhibitors raise survival in NSCLC.
Cancer Discov; 2014 Jan; 4(1):6. PubMed ID: 24402925
[TBL] [Abstract][Full Text] [Related]
25. Targeting the epidermal growth factor receptor a new strategy in cancer treatment.
Gianni L; Grasselli G
Suppl Tumori; 2002; 1(4):S60-1. PubMed ID: 12415824
[No Abstract] [Full Text] [Related]
26. [Prospect and Current Situation of Immune Checkpoint Inhibitors
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients].
Wang H; Yu X; Fan Y
Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):427-432. PubMed ID: 28641702
[TBL] [Abstract][Full Text] [Related]
27. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
Kerr KM; Nicolson MC
Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
[TBL] [Abstract][Full Text] [Related]
28. Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers.
Rosell R
J Clin Oncol; 2004 Apr; 22(7):1171-3. PubMed ID: 14981109
[No Abstract] [Full Text] [Related]
29. Immune checkpoint modulation for non-small cell lung cancer.
Soria JC; Marabelle A; Brahmer JR; Gettinger S
Clin Cancer Res; 2015 May; 21(10):2256-62. PubMed ID: 25979932
[TBL] [Abstract][Full Text] [Related]
30. Durvalumab boosts progression-free survival in NSCLC.
Gourd E
Lancet Oncol; 2018 Jan; 19(1):e11. PubMed ID: 29175147
[No Abstract] [Full Text] [Related]
31. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
Tsujino K; Kawaguchi T; Kubo A; Aono N; Nakao K; Koh Y; Tachibana K; Isa S; Takada M; Kurata T
J Thorac Oncol; 2009 Aug; 4(8):994-1001. PubMed ID: 19633474
[TBL] [Abstract][Full Text] [Related]
32. [Biological follow-up of patients with HIV treated with anti-PD-1 or anti-PD-L1 for non-small cell bronchial carcinoma: A task group proposal].
Guihot A; Cadranel J; Lambotte O; Lavolé A; Autran B; Spano JP
Rev Mal Respir; 2016 Jun; 33(6):419-21. PubMed ID: 27140903
[No Abstract] [Full Text] [Related]
33. NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer.
Hall CJ; Umeweni N; Knight H; Smith L
Lancet Oncol; 2016 Oct; 17(10):1357-1358. PubMed ID: 27567055
[No Abstract] [Full Text] [Related]
34. Immuno-oncology drugs jostle for first-line setting.
Mullard A
Nat Rev Drug Discov; 2016 Nov; 15(11):738. PubMed ID: 27807351
[No Abstract] [Full Text] [Related]
35. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
36. [New era in cancer therapy. Gefitinib: small molecule--strong action].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
[No Abstract] [Full Text] [Related]
37. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.
Med Lett Drugs Ther; 2017 Jan; 59(1513):22-23. PubMed ID: 28118650
[No Abstract] [Full Text] [Related]
38. Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab.
Turgeman I; Wollner M; Hassoun G; Bonstein L; Bar-Sela G
Anticancer Drugs; 2017 Aug; 28(7):811-814. PubMed ID: 28574922
[TBL] [Abstract][Full Text] [Related]
39. Non-small cell lung cancer: from targeted therapy to tailored therapy.
Malgieri S; Feliciano S; Bosso D; Federico P; Palmieri G; De Placido S; Di Lorenzo G; Buonerba C
Expert Opin Pharmacother; 2012 Sep; 13(13):1817-9. PubMed ID: 22803703
[No Abstract] [Full Text] [Related]
40. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
